Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06636435 | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | recruiting | Phase 1 | 66 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT03269526 | BATs Treatment for Pancreatic Cancer, Phase Ib/II | completed | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07547553 | A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | recruiting | Phase 1 / Phase 2 | 30 | Huahui HealthINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 155 | Plexium, Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 1 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05773105 | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | completed | Phase 1 / Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07116486 | A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07637786 | Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer | not yet recruiting | Phase 1 | 9 | Sichuan UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT07145450 | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | recruiting | Phase 1 / Phase 2 | 96 | Anocca ABOTHER_GOV | 4 | Jun 8, 2026 | clinicaltrials |
| NCT05419479 | Switch Maintenance in Pancreatic | suspended | Phase 1 / Phase 2 | 46 | James Cleary, MD, PhDOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624214 | Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors | not yet recruiting | Phase 1 | 198 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02379377 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | active not recruiting | Phase 1 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03257761 | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | active not recruiting | Phase 1 | 55 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT06266143 | A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 71 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | not yet recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04484909 | NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | active not recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05546879 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC(Liver-NET1) | active not recruiting | Phase 1 | 43 | University Hospital, GrenobleOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07481357 | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Dong-A ST Co., Ltd.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06904378 | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors | recruiting | Phase 1 | 48 | Shenzhen Xinhe BiomedicalINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 55 | West China HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07594548 | Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | not yet recruiting | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma(NYHCC) | not yet recruiting | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07493044 | An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials